Developer docs
API playgroundTry for free, no card

Search company profiles

Accurate International

Full company profile

uuid0002p81

Namestring
Accurate International
Legal namestring
创芯国际生物科技(广州)有限公司
Websiteurl
3dbudcare.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Accurate International (创芯国际), formally Chuangxin International Biotechnology (Guangzhou) Co., Ltd., is a China-based organoid technology platform founded in 2018 and headquartered in Guangzhou's Huangpu District. It operates an "organoid full lifecycle" platform that integrates tumor organoid modeling, disease-model and normal-tissue organoids, drug sensitivity evaluation, identification, immune co-culture, and gene editing, supported by an AI-powered AOD Organoid Big Database. The company is recognized as a National High-Tech Enterprise, Guangdong Province Organoid Engineering Technology Research Center, Guangdong Specialized and Innovative SME, and Guangdong IP Demonstration Enterprise, and holds 100+ patents covering organoid products and services.

The company generates revenue across three streams: (1) clinical testing services under the 蓓芯安® and 蓓芯康® brands, providing individualized organoid drug sensitivity testing — alone or combined with next-generation sequencing — to guide personalized anti-tumor drug selection for cancer patients; (2) new drug R&D services acting as a CRO for pharmaceutical companies, covering drug discovery through post-market evaluation; and (3) smart manufacturing equipment, selling proprietary instruments — Accuauto® automated cell smart laboratories, Auridrop® multi-dimensional immune co-culture workstations, and Accuro-Cult™ rotary CO2 incubators — to global research institutions. Distribution is direct enterprise sales to 200+ core hospitals domestically and to research institutions internationally, with strategic support from joint laboratories at China Pharmaceutical University and Zhuhai Macau University Research Institute, and a medical-supply-chain partnership with Shangpharma.

The company's go-to-market is sales-led, leveraging hospital networks, academic collaborations, industry conferences, and government designations. It has raised approximately RMB 200 million across two disclosed rounds — a RMB 100 million Pre-B led by Daocheng Caizhi in October 2022 and a RMB 100 million Series B led by Guangdong Technology Financial Group in May 2025. Notable commercial and scientific validation includes the world's first expert consensus on organoid drug sensitivity testing in precision oncology, a Cell Reports Medicine publication (IF 16.988) on patient-derived lung cancer organoids with Guangdong Provincial People's Hospital, and a dense cluster of municipal and regional awards in 2025–2026.

Short descriptiontext

Accurate International is a Guangzhou-based organoid technology platform providing clinical drug-sensitivity testing, CRO services for new drug R&D, and proprietary automated lab equipment to hospitals, pharmaceutical companies, and global research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organoid technology platform, drug sensitivity testing, precision medicine services, organoid drug discovery, automated cell laboratory equipment
Industry4 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Organoid biotechnology services and equipment
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1临床检测服务 (Clinical Testing Services)
TypeProfessional Services
Description

Provides organoid-based drug sensitivity testing for cancer patients to guide personalized anti-tumor drug selection. Revenue generated through individual patient testing fees and institutional contracts with hospitals.

bio-accurate.com
2新药研发服务 (New Drug R&D Services)
TypeProfessional Services
Description

Offers full-process evaluation from drug discovery, preclinical research, clinical research to post-market drug studies through organoid technology platform. Serves as a CRO providing contract research services to pharmaceutical companies.

bio-accurate.com
3智能制造/产品销售 (Smart Manufacturing Equipment Sales)
TypeHardware Sales
Description

Sells automated organoid laboratory equipment including Accuauto automated cell smart lab systems, Auridrop immune co-culture workstations, and Accuro-Cult rotary CO2 incubators to global research institutions.

bio-accurate.com
4类器官建模与相关技术服务
TypeProfessional Services
Description

Provides organoid modeling services for tumor, disease model, and normal tissue organoids, as well as organoid identification, gene editing, and related technical services.

bio-accurate.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1奥图优® Accuauto
Description

全自动细胞智慧实验室 (Fully automated cell smart laboratory)

bio-accurate.com
+4 more records
Core offering1 text field

Accurate International (Chuangxin International) operates an organoid full lifecycle technology platform delivering three integrated business lines: clinical drug sensitivity testing services for cancer patients via hospitals (蓓芯安® and 蓓芯康®), contract research and preclinical organoid-based evaluation services for pharmaceutical companies (CRO), and proprietary automated organoid laboratory equipment (Accuauto, Auridrop, Accuro-Cult) sold to research institutions, all backed by the AI-powered AOD organoid big database.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 32,000+ organoid models generated
+3 more records
Product overview1 text field

Accurate International (创芯国际) offers a comprehensive organoid full lifecycle technology platform with three core business segments: (1) Clinical Testing Services featuring 蓓芯安® (organoid drug sensitivity testing) and 蓓芯康® (organoid testing combined with next-generation sequencing); (2) New Drug R&D Services including organoid model platforms and a large organoid database (AOD); and (3) Intelligent Manufacturing products including 奥图优® Accuauto automated cell smart laboratory, 奥智因® Auridrop multi-dimensional immune co-culture workstation, and 奥智衡™ Accuro-Cult rotary CO2 incubator. The company positions itself as a global innovation benchmark in organoid technology, providing high-throughput, high-fidelity solutions for drug discovery, precision medicine, and regenerative medicine.

Product and service7 records
1Accuauto (奥图优®) Fully Automated Cell Smart Laboratory
CategoryIntelligent Manufacturing / Smart Laboratory Equipment
Description

Fully automated cell smart laboratory system for high-throughput, standardized, and digitized organoid production, sold to global research institutions requiring industrialized organoid manufacturing.

2Auridrop (奥智因®) Multi-dimensional Intelligent Organoid Immune Co-culture Workstation
CategoryIntelligent Manufacturing / Laboratory Equipment
Description

Multi-dimensional intelligent connected workstation enabling complex organoid-immune co-culture experiments for immunotherapy research, sold to research institutions globally.

3Accuro-Cult (奥智衡™) Rotary Automated CO2 Incubator
CategoryIntelligent Manufacturing / Laboratory Equipment
Description

Rotary automated CO2 incubator designed for consistent, high-throughput, standardized organoid culture maintenance, sold to research institutions.

4Beixin'an (蓓芯安®) Organoid Individualized Drug Sensitivity Testing
CategoryClinical Testing Service
Description

Phenotypic organoid-based drug sensitivity testing service that screens anti-tumor drug regimens for individual cancer patients to improve chemotherapy and targeted therapy response rates and reduce drug resistance.

5Beixinkang (蓓芯康®) Organoid Individualized Drug Sensitivity Testing & Next-Generation Sequencing
CategoryClinical Testing Service with Genomics
Description

Combined organoid drug sensitivity testing and next-generation sequencing service delivering comprehensive precision medicine analysis for oncology treatment decision support.

6Organoid-based New Drug R&D Services (CRO)
CategoryCRO / New Drug R&D Services
Description

Full-process CRO services covering drug discovery, preclinical research, clinical research, and post-market drug studies through the company's organoid technology platform, delivered to pharmaceutical companies.

7Organoid Modeling and Related Technical Services
CategoryOrganoid Modeling and Technical Services
Description

Service offering for tumor organoid, disease model organoid, and normal tissue organoid construction, including organoid identification and gene editing services delivered to researchers and biopharma clients.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1中山大学 - 张力/方文峰团队 (Sun Yat-sen University - Zhang Li & Fang Wenfeng Team)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-24
Description

First disclosure of non-small cell lung cancer patient drug resistance mechanisms using organoid-based molecular typing for precision treatment strategy. Joint research collaboration.

bio-accurate.com
2国家呼吸医学中心 (National Respiratory Medical Center)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-29
Description

Explored organoid technology advancements with the National Respiratory Medical Center, jointly advancing future respiratory medicine research.

bio-accurate.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-10
Description

Strategic cooperation signed between Shangpharma Medical Supply Chain and 创芯国际 for complementary advantages and innovative collaboration in the medical supply chain.

4广东省人民医院 - 杨衿记教授团队 (Guangdong Provincial People's Hospital - Professor Yang Jindi Team)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-19
Description

Major joint research published in Cell Reports Medicine (IF: 16.988) on using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response. Research funded by Guangdong high-level hospital construction project and national/provincial natural science funds.

bio-accurate.com
5珠海澳大科技研究院 (Zhuhai Macau University Research Institute)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-09-23
Description

Joint organoid laboratory established in Hengqin Guangdong-Macao Deep Cooperation Zone. Inauguration attended by officials from Guangzhou Science and Technology Bureau, Macau representative offices, and senior leadership from Macau University. Also serves as joint laboratory with Guangdong Organoid Research Center.

bio-accurate.com
6中国药科大学 (China Pharmaceutical University)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-08-27
Description

Established joint organoid laboratory and signed professional degree graduate school-level practice base agreement. Multiple pharmaceutical company representatives attended the ceremony including Jiangsu Zhengdaqingtian, Nanjing Boshimedia, Nanjing Yaojiekang, Jiangsu Aosaikang, Shenghe Pharmaceutical, and other pharma partners.

bio-accurate.com
7江苏正大天晴 (Jiangsu Zhengdaqingtian)
Strategic tierMinorTypeOthersAnnounced on2022-08-27
Description

Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.

bio-accurate.com
8圣和药业 (Shenghe Pharmaceutical)
Strategic tierMinorTypeOthersAnnounced on2022-08-27
Description

Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.

bio-accurate.com
Strategic tierMinorTypeOthersAnnounced on2022-08-27
Description

Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.

10中国抗癌协会肿瘤标志专业委员会 (CACA Tumor Marker Professional Committee)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-07-10
Description

Co-published the world's first expert consensus on clinical application of organoid drug sensitivity testing for guiding precision oncology treatment. Published jointly with CACA Tumor Marker Professional Committee, Chinese Journal of Cancer Prevention and Treatment, Guangdong Organoid Engineering Technology Research Center, and Guangdong Precision Medicine Application Society Organoid and Organ Chip Branch.

bio-accurate.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Xilis
TypeEmerging player
Description

Xilis is a US-based precision oncology company developing patient-derived organoid platforms for drug response prediction and cancer therapy selection. It overlaps with Accurate International's clinical drug sensitivity testing business and competes for pharmaceutical partnerships in the same oncology precision medicine space.

TypeDirect peer
Description

DefiniGEN provides iPSC-derived organoid and cell-based disease modeling services for drug discovery and preclinical research. It competes directly with Accurate International in offering organoid-based services to pharma R&D teams, particularly in metabolic and liver disease indications.

TypeBroad incumbent
Description

Pharmaron is a global CRO/CDMO offering integrated drug discovery, preclinical, and clinical services from China-anchored facilities. It is a broad incumbent competing with Accurate International for pharmaceutical CRO contracts, though it lacks a dedicated organoid platform.

TypeEmerging player
Description

Emulate develops organ-on-chip technology and automated lab systems for drug development and disease modeling. It overlaps with Accurate International's smart manufacturing equipment line (Accuauto, Auridrop) and competes in supplying organoid/organ-chip platforms to global research institutions.

5Hubrecht Organoid Technology
TypeOthers
Description

Hubrecht Organoid Technology (HUB) is the foundational organoid technology organization established from the Hans Clevers lab, holding core patents on LGR5+ stem cell organoid technology. It is comparable as the upstream licensor/ecosystem reference for the entire organoid industry in which Accurate International operates.

TypeBroad incumbent
Description

WuXi AppTec is the largest Chinese CRO offering preclinical, clinical, and biologics services globally. While not an organoid specialist, its preclinical and clinical CRO offerings overlap with Accurate International's new drug R&D services, and it competes for the same pharmaceutical customer budget allocations in China.

7Tempus AI
TypeBroad incumbent
Description

Tempus AI is a US precision medicine company combining molecular data, AI, and clinical testing to support oncology treatment decisions. While not an organoid specialist, its AI-enabled precision oncology decision support overlaps thematically with Accurate International's AOD database and AI-drug-response prediction capabilities.

TypeDirect peer
Description

Crown Bioscience is a global preclinical CRO offering patient-derived xenograft (PDX) and organoid services for oncology drug discovery. It is one of the most direct competitors to Accurate International's organoid CRO business, serving the same pharmaceutical customers with overlapping preclinical-to-clinical translational offerings.

9CN Bio
TypeEmerging player
Description

CN Bio is a UK-based organ-on-chip and microphysiological systems company offering preclinical drug testing platforms. It is comparable to Accurate International in providing advanced in vitro models for pharma R&D, though with a stronger focus on organ-on-chip versus organoid technologies.

TypeRegional player
Description

BeBetter Med is a Chinese organoid and precision medicine company developing patient-derived organoid models for clinical drug sensitivity testing and pharmaceutical research. It is the closest domestic Chinese peer to Accurate International, competing in the same hospital-channel and CRO services markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accurate International

Organoid biotechnology services and equipment3dbudcare.com

Accurate International is a Guangzhou-based organoid technology platform providing clinical drug-sensitivity testing, CRO services for new drug R&D, and proprietary automated lab equipment to hospitals, pharmaceutical companies, and global research institutions.

What Accurate International does

Accurate International (创芯国际), formally Chuangxin International Biotechnology (Guangzhou) Co., Ltd., is a China-based organoid technology platform founded in 2018 and headquartered in Guangzhou's Huangpu District. It operates an "organoid full lifecycle" platform that integrates tumor organoid modeling, disease-model and normal-tissue organoids, drug sensitivity evaluation, identification, immune co-culture, and gene editing, supported by an AI-powered AOD Organoid Big Database. The company is recognized as a National High-Tech Enterprise, Guangdong Province Organoid Engineering Technology Research Center, Guangdong Specialized and Innovative SME, and Guangdong IP Demonstration Enterprise, and holds 100+ patents covering organoid products and services.

The company generates revenue across three streams: (1) clinical testing services under the 蓓芯安® and 蓓芯康® brands, providing individualized organoid drug sensitivity testing — alone or combined with next-generation sequencing — to guide personalized anti-tumor drug selection for cancer patients; (2) new drug R&D services acting as a CRO for pharmaceutical companies, covering drug discovery through post-market evaluation; and (3) smart manufacturing equipment, selling proprietary instruments — Accuauto® automated cell smart laboratories, Auridrop® multi-dimensional immune co-culture workstations, and Accuro-Cult™ rotary CO2 incubators — to global research institutions. Distribution is direct enterprise sales to 200+ core hospitals domestically and to research institutions internationally, with strategic support from joint laboratories at China Pharmaceutical University and Zhuhai Macau University Research Institute, and a medical-supply-chain partnership with Shangpharma.

The company's go-to-market is sales-led, leveraging hospital networks, academic collaborations, industry conferences, and government designations. It has raised approximately RMB 200 million across two disclosed rounds — a RMB 100 million Pre-B led by Daocheng Caizhi in October 2022 and a RMB 100 million Series B led by Guangdong Technology Financial Group in May 2025. Notable commercial and scientific validation includes the world's first expert consensus on organoid drug sensitivity testing in precision oncology, a Cell Reports Medicine publication (IF 16.988) on patient-derived lung cancer organoids with Guangdong Provincial People's Hospital, and a dense cluster of municipal and regional awards in 2025–2026.

Accurate International firmographics

Firmographics
Name
Accurate International
Legal name
创芯国际生物科技(广州)有限公司
Website
https://3dbudcare.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Accurate International is a Guangzhou-based organoid technology platform providing clinical drug-sensitivity testing, CRO services for new drug R&D, and proprietary automated lab equipment to hospitals, pharmaceutical companies, and global research institutions.
Ownership category
akta.pro rank

Accurate International industry classification

Industry
Product category
Organoid biotechnology services and equipment
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Organoid technology platform
  • Drug sensitivity testing
  • Precision medicine services
  • Organoid drug discovery
  • Automated cell laboratory equipment

Where Accurate International is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Accurate International business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. 临床检测服务 (Clinical Testing Services): Provides organoid-based drug sensitivity testing for cancer patients to guide personalized anti-tumor drug selection. Revenue generated through individual patient testing fees and institutional contracts with hospitals.
  2. 新药研发服务 (New Drug R&D Services): Offers full-process evaluation from drug discovery, preclinical research, clinical research to post-market drug studies through organoid technology platform. Serves as a CRO providing contract research services to pharmaceutical companies.
  3. 智能制造/产品销售 (Smart Manufacturing Equipment Sales): Sells automated organoid laboratory equipment including Accuauto automated cell smart lab systems, Auridrop immune co-culture workstations, and Accuro-Cult rotary CO2 incubators to global research institutions.
  4. 类器官建模与相关技术服务: Provides organoid modeling services for tumor, disease model, and normal tissue organoids, as well as organoid identification, gene editing, and related technical services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Accurate International product offering

Product offering

Core offering

Accurate International (Chuangxin International) operates an organoid full lifecycle technology platform delivering three integrated business lines: clinical drug sensitivity testing services for cancer patients via hospitals (蓓芯安® and 蓓芯康®), contract research and preclinical organoid-based evaluation services for pharmaceutical companies (CRO), and proprietary automated organoid laboratory equipment (Accuauto, Auridrop, Accuro-Cult) sold to research institutions, all backed by the AI-powered AOD organoid big database.

Product overview

Accurate International (创芯国际) offers a comprehensive organoid full lifecycle technology platform with three core business segments: (1) Clinical Testing Services featuring 蓓芯安® (organoid drug sensitivity testing) and 蓓芯康® (organoid testing combined with next-generation sequencing); (2) New Drug R&D Services including organoid model platforms and a large organoid database (AOD); and (3) Intelligent Manufacturing products including 奥图优® Accuauto automated cell smart laboratory, 奥智因® Auridrop multi-dimensional immune co-culture workstation, and 奥智衡™ Accuro-Cult rotary CO2 incubator. The company positions itself as a global innovation benchmark in organoid technology, providing high-throughput, high-fidelity solutions for drug discovery, precision medicine, and regenerative medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • 奥图优® Accuauto: 全自动细胞智慧实验室 (Fully automated cell smart laboratory)
  • 奥智因® Auridrop
  • 奥智衡™ Accuro-Cult
  • 蓓芯安®
  • 蓓芯康®

Products and services

  • Accuauto (奥图优®) Fully Automated Cell Smart Laboratory Fully automated cell smart laboratory system for high-throughput, standardized, and digitized organoid production, sold to global research institutions requiring industrialized organoid manufacturing.
  • Auridrop (奥智因®) Multi-dimensional Intelligent Organoid Immune Co-culture Workstation Multi-dimensional intelligent connected workstation enabling complex organoid-immune co-culture experiments for immunotherapy research, sold to research institutions globally.
  • Accuro-Cult (奥智衡™) Rotary Automated CO2 Incubator Rotary automated CO2 incubator designed for consistent, high-throughput, standardized organoid culture maintenance, sold to research institutions.
  • Beixin'an (蓓芯安®) Organoid Individualized Drug Sensitivity Testing Phenotypic organoid-based drug sensitivity testing service that screens anti-tumor drug regimens for individual cancer patients to improve chemotherapy and targeted therapy response rates and reduce drug resistance.
  • Beixinkang (蓓芯康®) Organoid Individualized Drug Sensitivity Testing & Next-Generation Sequencing Combined organoid drug sensitivity testing and next-generation sequencing service delivering comprehensive precision medicine analysis for oncology treatment decision support.
  • Organoid-based New Drug R&D Services (CRO) Full-process CRO services covering drug discovery, preclinical research, clinical research, and post-market drug studies through the company's organoid technology platform, delivered to pharmaceutical companies.
  • Organoid Modeling and Related Technical Services Service offering for tumor organoid, disease model organoid, and normal tissue organoid construction, including organoid identification and gene editing services delivered to researchers and biopharma clients.

Quantifiable outcome

  • 32,000+ organoid models generated
  • +3 more outcomes

Companies that use Accurate International

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Accurate International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Accurate International partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • 中山大学 - 张力/方文峰团队 (Sun Yat-sen University - Zhang Li & Fang Wenfeng Team)coreStrategic or Co-development Partner · 24 May 2024First disclosure of non-small cell lung cancer patient drug resistance mechanisms using organoid-based molecular typing for precision treatment strategy. Joint research collaboration.
  • 国家呼吸医学中心 (National Respiratory Medical Center)coreStrategic or Co-development Partner · 29 April 2024Explored organoid technology advancements with the National Respiratory Medical Center, jointly advancing future respiratory medicine research.
  • 上药医疗供应链 (Shangpharma Medical Supply Chain)coreStrategic or Co-development Partner · 10 April 2024Strategic cooperation signed between Shangpharma Medical Supply Chain and 创芯国际 for complementary advantages and innovative collaboration in the medical supply chain.
  • 广东省人民医院 - 杨衿记教授团队 (Guangdong Provincial People's Hospital - Professor Yang Jindi Team)flagshipStrategic or Co-development Partner · 19 January 2023Major joint research published in Cell Reports Medicine (IF: 16.988) on using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response. Research funded by Guangdong high-level hospital construction project and national/provincial natural science funds.
  • 珠海澳大科技研究院 (Zhuhai Macau University Research Institute)flagshipStrategic or Co-development Partner · 23 September 2022Joint organoid laboratory established in Hengqin Guangdong-Macao Deep Cooperation Zone. Inauguration attended by officials from Guangzhou Science and Technology Bureau, Macau representative offices, and senior leadership from Macau University. Also serves as joint laboratory with Guangdong Organoid Research Center.
  • 中国药科大学 (China Pharmaceutical University)flagshipStrategic or Co-development Partner · 27 August 2022Established joint organoid laboratory and signed professional degree graduate school-level practice base agreement. Multiple pharmaceutical company representatives attended the ceremony including Jiangsu Zhengdaqingtian, Nanjing Boshimedia, Nanjing Yaojiekang, Jiangsu Aosaikang, Shenghe Pharmaceutical, and other pharma partners.
  • 江苏正大天晴 (Jiangsu Zhengdaqingtian)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
  • 圣和药业 (Shenghe Pharmaceutical)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
  • 先声药业 (Simcere Pharmaceutical)minorOthers · 27 August 2022Pharmaceutical company representative attending joint laboratory inauguration ceremony with China Pharmaceutical University.
  • 中国抗癌协会肿瘤标志专业委员会 (CACA Tumor Marker Professional Committee)flagshipStrategic or Co-development Partner · 10 July 2022Co-published the world's first expert consensus on clinical application of organoid drug sensitivity testing for guiding precision oncology treatment. Published jointly with CACA Tumor Marker Professional Committee, Chinese Journal of Cancer Prevention and Treatment, Guangdong Organoid Engineering Technology Research Center, and Guangdong Precision Medicine Application Society Organoid and Organ Chip Branch.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Accurate International competitors and assessment

Company assessment

Emerging players

  • Xilis: Xilis is a US-based precision oncology company developing patient-derived organoid platforms for drug response prediction and cancer therapy selection. It overlaps with Accurate International's clinical drug sensitivity testing business and competes for pharmaceutical partnerships in the same oncology precision medicine space.
  • Emulate: Emulate develops organ-on-chip technology and automated lab systems for drug development and disease modeling. It overlaps with Accurate International's smart manufacturing equipment line (Accuauto, Auridrop) and competes in supplying organoid/organ-chip platforms to global research institutions.
  • CN Bio: CN Bio is a UK-based organ-on-chip and microphysiological systems company offering preclinical drug testing platforms. It is comparable to Accurate International in providing advanced in vitro models for pharma R&D, though with a stronger focus on organ-on-chip versus organoid technologies.

Direct peers

  • DefiniGEN: DefiniGEN provides iPSC-derived organoid and cell-based disease modeling services for drug discovery and preclinical research. It competes directly with Accurate International in offering organoid-based services to pharma R&D teams, particularly in metabolic and liver disease indications.
  • Crown Bioscience: Crown Bioscience is a global preclinical CRO offering patient-derived xenograft (PDX) and organoid services for oncology drug discovery. It is one of the most direct competitors to Accurate International's organoid CRO business, serving the same pharmaceutical customers with overlapping preclinical-to-clinical translational offerings.

Broad incumbents

  • Pharmaron: Pharmaron is a global CRO/CDMO offering integrated drug discovery, preclinical, and clinical services from China-anchored facilities. It is a broad incumbent competing with Accurate International for pharmaceutical CRO contracts, though it lacks a dedicated organoid platform.
  • WuXi AppTec: WuXi AppTec is the largest Chinese CRO offering preclinical, clinical, and biologics services globally. While not an organoid specialist, its preclinical and clinical CRO offerings overlap with Accurate International's new drug R&D services, and it competes for the same pharmaceutical customer budget allocations in China.
  • Tempus AI: Tempus AI is a US precision medicine company combining molecular data, AI, and clinical testing to support oncology treatment decisions. While not an organoid specialist, its AI-enabled precision oncology decision support overlaps thematically with Accurate International's AOD database and AI-drug-response prediction capabilities.

Others

  • Hubrecht Organoid Technology: Hubrecht Organoid Technology (HUB) is the foundational organoid technology organization established from the Hans Clevers lab, holding core patents on LGR5+ stem cell organoid technology. It is comparable as the upstream licensor/ecosystem reference for the entire organoid industry in which Accurate International operates.

Regional players

  • BeBetter Med: BeBetter Med is a Chinese organoid and precision medicine company developing patient-derived organoid models for clinical drug sensitivity testing and pharmaceutical research. It is the closest domestic Chinese peer to Accurate International, competing in the same hospital-channel and CRO services markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Accurate International compliance and trust

Trust signal

Compliance3 records

Accurate International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accurate International leadership team

Management profile

Number of profiles

Profiles3 records

Accurate International funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accurate International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accurate International

What does Accurate International do?

Accurate International (Chuangxin International) operates an organoid full lifecycle technology platform delivering three integrated business lines: clinical drug sensitivity testing services for cancer patients via hospitals (蓓芯安® and 蓓芯康®), contract research and preclinical organoid-based evaluation services for pharmaceutical companies (CRO), and proprietary automated organoid laboratory equipment (Accuauto, Auridrop, Accuro-Cult) sold to research institutions, all backed by the AI-powered AOD organoid big database.

Is Accurate International a public or private company?

Accurate International is a private company. It is classified as venture growth investor backed and is currently operating.

When was Accurate International founded?

Accurate International was founded in 2018. It employs 1 to 10 people.

Where is Accurate International based?

Accurate International is headquartered in Guangzhou, China, in the Asia region.

How does Accurate International make money?

Four revenue lines are on record. 临床检测服务 (Clinical Testing Services) is the primary driver. The others are 新药研发服务 (New Drug R&D Services), 智能制造/产品销售 (Smart Manufacturing Equipment Sales) and 类器官建模与相关技术服务.

Who are Accurate International's main competitors?

Emerging players on record are Xilis, Emulate and CN Bio. Direct peers are DefiniGEN and Crown Bioscience. Broad incumbents are Pharmaron, WuXi AppTec and Tempus AI. Hubrecht Organoid Technology is listed as an others. BeBetter Med is listed as a regional player.

Does Accurate International have an API?

No public API is recorded for Accurate International.

What industry is Accurate International in?

Accurate International's product category is Organoid biotechnology services and equipment. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales